NCT02614066 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 55
- group Id
- BG004
- value
- 100
- units
- Participants
- groups
- description
- Participants with r/r B-ALL received conditioning chemotherapy (fludarabine 25 mg/m\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\^2 IV over 60 minutes on Day -2) followed by a single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered IV at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \> 100 kg, a maximum flat dose of 2 x 10\^8 anti-CD19 CAR T cells/kg of body weight was administered.
- id
- BG000
- title
- Phase 1: 2 x 10^6 Anti-CD19 CAR T Cells/kg
- description
- Participants with r/r B-ALL received conditioning chemotherapy (fludarabine 25 mg/m\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\^2 IV over 60 minutes on Day -2) followed by a single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered IV at a target dose of 1 x 10\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \> 100 kg, a maximum flat dose of 1 x 10\^8 anti-CD19 CAR T cells/kg of body weight was administered.
- id
- BG001
- title
- Phase 1: 1 x 10^6 Anti-CD19 CAR T Cells/kg
- description
- Participants with r/r B-ALL received conditioning chemotherapy (fludarabine 25 mg/m\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\^2 IV over 60 minutes on Day -2) followed by a single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered IV at a target dose of 0.5 x 10\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \> 100 kg, a maximum flat dose of 0.5 x 10\^8 anti-CD19 CAR T cells/kg of body weight was administered.
- id
- BG002
- title
- Phase 1: 0.5 x 10^6 Anti-CD19 CAR T Cells/kg
- description
- Participants with r/r B-ALL received conditioning chemotherapy (fludarabine 25 mg/m\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\^2 IV over 60 minutes on Day -2) followed by a single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered IV at a target dose of 1 x 10\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \> 100 kg, a maximum flat dose of 1 x 10\^8 anti-CD19 CAR T cells/kg of body weight was administered.
- id
- BG003
- title
- Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
- description
- Total of all reporting groups
- id
- BG004
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 13.8
- value
- 38
- group Id
- BG001
- spread
- 17.6
- value
- 46
- group Id
- BG002
- spread
- 16.7
- value
- 46
- group Id
- BG003
- spread
- 16.1
- value
- 42
- group Id
- BG004
- spread
- 16.3
- value
- 43
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- title
- <=18 years
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 47
- group Id
- BG004
- value
- 84
- title
- Between 18 and 65 years
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 15
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 22
- group Id
- BG004
- value
- 45
- title
- Female
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 33
- group Id
- BG004
- value
- 55
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 28
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 42
- group Id
- BG004
- value
- 70
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- title
- Not collected
- title
- Ethnicity
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 6
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 37
- group Id
- BG004
- value
- 76
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 11
- title
- Other or More Than One Race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 4
- title
- Not collected
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- title
- Race
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 10
- title
- France
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- title
- Germany
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- title
- Netherlands
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 41
- group Id
- BG004
- value
- 86
- title
- United States
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- population Description
- The Safety Analysis Set included all participants treated with any dose of brexucabtagene autoleucel.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 55
- group Id
- BG004
- value
- 100
- units
- Participants
- groups
- description
- Participants with r/r B-ALL received conditioning chemotherapy (fludarabine 25 mg/m\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\^2 IV over 60 minutes on Day -2) followed by a single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered IV at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \> 100 kg, a maximum flat dose of 2 x 10\^8 anti-CD19 CAR T cells/kg of body weight was administered.
- id
- BG000
- title
- Phase 1: 2 x 10^6 Anti-CD19 CAR T Cells/kg
- description
- Participants with r/r B-ALL received conditioning chemotherapy (fludarabine 25 mg/m\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\^2 IV over 60 minutes on Day -2) followed by a single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered IV at a target dose of 1 x 10\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \> 100 kg, a maximum flat dose of 1 x 10\^8 anti-CD19 CAR T cells/kg of body weight was administered.
- id
- BG001
- title
- Phase 1: 1 x 10^6 Anti-CD19 CAR T Cells/kg
- description
- Participants with r/r B-ALL received conditioning chemotherapy (fludarabine 25 mg/m\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\^2 IV over 60 minutes on Day -2) followed by a single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered IV at a target dose of 0.5 x 10\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \> 100 kg, a maximum flat dose of 0.5 x 10\^8 anti-CD19 CAR T cells/kg of body weight was administered.
- id
- BG002
- title
- Phase 1: 0.5 x 10^6 Anti-CD19 CAR T Cells/kg
- description
- Participants with r/r B-ALL received conditioning chemotherapy (fludarabine 25 mg/m\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\^2 IV over 60 minutes on Day -2) followed by a single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered IV at a target dose of 1 x 10\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \> 100 kg, a maximum flat dose of 1 x 10\^8 anti-CD19 CAR T cells/kg of body weight was administered.
- id
- BG003
- title
- Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
- description
- Total of all reporting groups
- id
- BG004
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 13.8
- value
- 38
- group Id
- BG001
- spread
- 17.6
- value
- 46
- group Id
- BG002
- spread
- 16.7
- value
- 46
- group Id
- BG003
- spread
- 16.1
- value
- 42
- group Id
- BG004
- spread
- 16.3
- value
- 43
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- title
- <=18 years
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 47
- group Id
- BG004
- value
- 84
- title
- Between 18 and 65 years
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 15
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 22
- group Id
- BG004
- value
- 45
- title
- Female
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 33
- group Id
- BG004
- value
- 55
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 28
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 42
- group Id
- BG004
- value
- 70
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- title
- Not collected
- title
- Ethnicity
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 6
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 37
- group Id
- BG004
- value
- 76
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 11
- title
- Other or More Than One Race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 4
- title
- Not collected
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- title
- Race
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 10
- title
- France
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- title
- Germany
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- title
- Netherlands
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 41
- group Id
- BG004
- value
- 86
- title
- United States
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- population Description
- The Safety Analysis Set included all participants treated with any dose of brexucabtagene autoleucel.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle